PCRX Pacira Biosciences Inc.

National Safety Council and Pacira BioSciences Partner to Launch an Employee-Based Program Focused on Opioid Use and Misuse

National Safety Council and Pacira BioSciences Partner to Launch an Employee-Based Program Focused on Opioid Use and Misuse

Initiative educates employees and their family members on the importance of preventing opioid misuse and addiction

TAMPA, Fla. and ITASCA, Ill., June 16, 2022 (GLOBE NEWSWIRE) -- The National Safety Council, America’s leading nonprofit safety advocate, and Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the launch of their partnership and the Connect2Prevent program. Connect2Prevent is an innovative employee-family educational program that increases awareness and prevention of opioid addiction.

NSC created a comprehensive curriculum designed to educate employees on the risks associated with opioids and provide them with the tools to have meaningful discussions with adolescent family members. The curriculum includes 10-12 weeks of engaging lessons on opioids, addiction, stigma, risk factors for substance use, refusal skills, harm reduction, how to talk to doctors about opioid alternatives and more. The lessons provide easy-to-understand education, action steps and evidence-based tools to connect and communicate with teens.

“As an organization committed to eliminating the leading causes of preventable death, we recognize the opportunity education presents to curtail the tragic impact of opioid addiction and misuse,” said Jenny Burke, vice president of impairment practice at NSC. “We are committed to saving lives by providing information and resources about the risks of opioids and opioid misuse to help employees and their loved ones have thoughtful conversations on this topic. Our partnership with Pacira is a significant step in the right direction toward supporting these efforts.”

Connect2Prevent uses a 2Gen approach, giving employees information about opioids and how to communicate and connect with their teens. The program has the potential to impact families across generations. Connect2Prevent supports employees and their families through this curriculum and incorporates input and ideas provided by teens for how the adults in their lives can talk with them about this important topic into the lessons.

“Children who use prescription opioids before 12th grade have a 33% higher risk of opioid misuse as an adult,” said Dave Stack, chief executive officer and chairman of Pacira BioSciences, Inc. “Education is a critical component in the fight against the opioid crisis, and raising awareness to the availability of non-opioid options to treat both acute and chronic pain is central to the Pacira mission to improve patient care.”

The program will be piloted this summer, with participants receiving weekly lessons. Each lesson includes educational information, action steps and ways to connect and communicate with teens, including evidence-based motivational interviewing strategies. Pilot participants will have the opportunity to review and provide feedback on the program before it is launched publicly in 2023.

About the National Safety Council

The National Safety Council is America's leading nonprofit safety advocate and has been for more than 100 years. As a mission-based organization, we work to eliminate the leading causes of preventable death and injury, focusing our efforts on the workplace, roadway, and impairment. We create a culture of safety to not only keep people safer at work, but also beyond the workplace so they can live their fullest lives.

About Pacira

Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera°®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit

Investor Contact:

Susan Mesco, (973) 451-4030

Media Contact:

Coyne Public Relations

Kristin Capone, (973) 588-2108

NSC Media Contacts:

Erin McDermott, (630) 775-2037

Senior Manager, Communications

Jennifer Schallmoser

Media Relations Coordinator, (630) 775-2307



EN
16/06/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacira Biosciences Inc.

David Carlson ... (+8)
  • David Carlson
  • David Nierengarten
  • Dennis Pak
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Sam Ravina
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VRTX VERTEX PHARMACEUTICALS INCORPORATED
SRPT SAREPTA THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RGNX REGENXBIO INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MNKD MANNKIND CORP.
LL LUMBER LIQUIDATORS HOLDINGS INC.
KURA KURA ONCOLOGY INC.
HD HOME DEPOT INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
TSC TRISTATE CAPITAL HOLDINGS INC
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
PK PARK HOTELS & RESORTS INC.
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
OVID OVID THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
VRNA VERONA PHARMA ADS
SE SEA ADS
AMD ADVANCED MICRO DEVICES INC.
APLS APELLIS PHARMACEUTICALS
UBX UNITY BIOTECHNOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
AX AXOS FINANCIAL INC.
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
IMUX IMMUNIC INC
GOSS GOSSAMER BIO
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
PASG PASSAGE BIO
ACET ADICET BIO INC
ASO ACADEMY SPORTS AND OUTDOORS
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
GBIO GENERATION BIO
PRAX PRAXIS PRECISION MEDICINES
COGT COGENT BIOSCIENCES INC
VOR VOR BIOPHARMA
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
SBTX SILVERBACK THERAPEUTICS
TNGX TANGO THERAPEUTICS
LBPH INC
IKNA LONGBOARD PHARMACEUTICALS
TCRX IKENA ONCOLOGY INC
VERA TSCAN THERAPEUTICS INC
HOWL VERA THERAPEUTICS INC
GLUE WEREWOLF THERAPEUTICS INC
AVTE MONTE ROSA THERAPEUTICS INC
CMPX AEROVATE THERAPEUTICS INC
GMTX COMPASS THERAPEUTICS
JANX GEMINI THERAPEUTICS INC
VIGL JANUX THERAPEUTICS INC
MLTX VIGIL NEUROSCIENCE INC
TYRA MOONLAKE IMMUNOTHERAPEUTICS
PEPG TYRA BIOSCIENCES INC
HR PEPGEN INC
EWTX HEALTHCARE TRUST OF AMERICA INC.
PRME EDGEWISE THERAPEUTICS INC
OCS PRIME MEDICINE INC
APGE OCULIS HOLDING AG
DNTH APOGEE THERAPEUTICS INC
DIANTHUS THERAPEUTICS INC
 PRESS RELEASE

Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual ...

Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference TAMPA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 23rd Annual Needham Virtual Healthcare Conference at 8:00 AM ET on Monday, April 8, 2024. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at . A replay of the webcast will also be available for two weeks following the event. About Pacira          Pacira BioSciences, Inc. (Nasdaq: PCRX)...

Wedbush Research
  • Wedbush Research
LOGN LOGITECH INTERNATIONAL S.A.
KMX CARMAX INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
RHP RYMAN HOSPITALITY PROPERTIES INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
NCMI NATIONAL CINEMEDIA INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MTH MERITAGE HOMES CORPORATION
LGIH LGI HOMES INC.
LEN LENNAR CORPORATION CLASS A
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
IMAX IMAX CORPORATION
GPRO GOPRO INC. CLASS A
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CNK CINEMARK HOLDINGS INC.
CMRX CHIMERIX INC
CCS CENTURY COMMUNITIES INC.
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
NFLX NETFLIX INC.
DHI D.R. HORTON INC.
FRX_CN FENNEC PHARMACEUTICALS
PVH PVH CORP.
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
ROKU ROKU INC. CLASS A
AMZN AMAZON.COM INC.
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
BCEL ATRECA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
PRAX PRAXIS PRECISION MEDICINES
FUBO FUBOTV
CURA CURALEAF HOLDINGS
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
LBPH LONGBOARD PHARMACEUTICALS
THRX THESEUS PHARMACEUTICALS
DSGN INC.
ATXS DESIGN THERAPEUTICS INC
AVTE ASTRIA THERAPEUTICS INC
RLYB AEROVATE THERAPEUTICS INC
KRTX RALLYBIO CORP
FUSN KARUNA THERAPEUTICS INC
VIGL FUSION PHARMACEUTICALS INC
EWTX VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC
David Carlson ... (+9)
  • David Carlson
  • David Nierengarten
  • Dennis Pak
  • Laura Chico
  • Liana Moussatos
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Sam Ravina
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
BCEL ATRECA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
LBPH LONGBOARD PHARMACEUTICALS
THRX THESEUS PHARMACEUTICALS
DSGN INC.
ATXS DESIGN THERAPEUTICS INC
AVTE ASTRIA THERAPEUTICS INC
RLYB AEROVATE THERAPEUTICS INC
KRTX RALLYBIO CORP
FUSN KARUNA THERAPEUTICS INC
VIGL FUSION PHARMACEUTICALS INC
EWTX VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC
 PRESS RELEASE

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Ad...

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee -- PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis -- -- Designation supported by encouraging preliminary data from 72-patient Phase 1 study -- -- 52-Week Data Accepted for Presentation at OARSI 2024 and 104-week data to be submitted for presentation later this year -- TAMPA, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry lead...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch